Skip to main content

Table 3 Association with relapse in the study group for the G2I and for various clinicopathological parameters

From: An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis

 

Univariate analysis

Multivariate analysis

Clinicopathological parameters

All(a) n(%)

No Relapse n(%)

Relapse n(%)

OR [CI 95%]

p

OR [CI 95%]

p

G2I (b)

       

Class 1

19 (14)

18 (20)

1 (2,2)

0,16[0,2-1,2]

0,08

0,24[0.03-2]

0.19

Class2

88 (65)

65 (72,2)

23 (51,1)

1

 

1

 

Class3

28 (21)

7 (7,8)

21 (46,7)

8,5[3 ,2-22,6]

<0,001

11.9[4.2-34.1]

<0.001

SBR Grade (c)

     

rejected

 

1

25 (18)

21 (23,3)

4 (8,9)

1

   

2

71 (53)

46 (51,1)

25 (55,6)

2,9[0,9-9,2]

0,08

  

3

39 (29)

23 (25,6)

16 (35,6)

3,7[1,05-12,7]

0,04

  

Histological size

     

rejected

 

≤ 20 mm.

90 (67)

67 (74,4)

23 (51,1)

1

   

> 20 mm.

45 (33)

23 (25,6)

22 (48,9)

2,8[1, 3–5, 9]

0,008

  

HR status (d)

       

HR-

19 (14)

12 (13,3)

7 (15,6)

1,19[0 ,44-

0,72

  

HR+

116 (86)

78 (86,7)

38 (84,4)

3,3]

   

NPI (e)

       

1 + 2

30 (22)

24 (26,7)

6 (13,3)

1

 

1

 

3

85 (63)

58 (64,4)

27 (60)

1,8[0,7-5,1]

0,23

1.38[0.4-4.4]

0.6

4

20 (15)

8 (8,9)

12 (26,7)

6[1,7-21,3]

0,006

7.2[1.8-29.3

0.006

TP53 alteration

       

no

115 (85)

73 (81,1)

31 (68,9)

1

   

yes

20 (15)

17 (18,9)

14 (31,1)

1,9[0,9-4,4]

0,11

  

mib1 (f)

     

rejected

 

<20%

93 (69)

67 (74,4)

26 (57,8)

1

   

≥20%

42 (31)

23 (25,6)

19 (42,2)

2,1[1–4,5]

0,05

  

IHC intrinsic class (g)

LA

83 (62)

59 (67)

24 (53,3)

1

   

LB + Her2+ Basal

50 (38)

29 (33)

21 (37,6)

1,8[0,85-3,7]

0,12

  

nd

2

2

     
  1. (a) n: Number of tumors; % in parentheses; (b) G2I: Three classes of genomics instability index as defined here; (c) SBR: Scarff, Bloom and Richardson grade; (d) HR: Hormonal Receptor; HR-: negative hormonal receptor status evaluated by immunohistochemistry (IHC) with a threshold of 10% of tumors cells; (e) NPI: Nottingham Prognostic Index, 1 + 2: good or excellent, 3: moderate, 4: poor; (f) immunohistochemistry expression of mib1; (g) immunohistochemical intrinsic class: LA: Luminal A for HR+-tumors with mib1 expression in less than 20% of tumor cells, LB: Luminal B for HR+-tumors with mib1 expression in at least 20% of tumor cells or with Her2 score of 3, Her2: Her2-enriched tumors for HR- and Her2+-tumors, Basal for HR- and Her2--tumors that express at least one of the following protein in more than 10% of tumor cells: egfr, ck5/6, or vimentin;